General Information of Drug (ID: DM8FSPV)

Drug Name
JTZ-951 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anaemia 3A90 Phase 3 [1]
Cross-matching ID
PubChem CID
50899324
CAS Number
CAS 1262132-81-9
TTD Drug ID
DM8FSPV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclopirox DMN5T2A Cutaneous candidiasis 1F23.14 Approved [3]
AKB-6548 DM2EJM3 Anaemia 3A90 Phase 3 [4]
BAY 853934 DM407I6 Anaemia 3A90 Phase 3 [5]
FG-2216 DM7RYL4 Kidney disease GC2Z Phase 2 [6]
DS-1093 DM42KZW Anemia 3A00-3A9Z Phase 1 [7]
ZYAN1 DM796RI Anaemia 3A90 Phase 1 [8]
JNJ-42905343 DMCNBHY Anaemia 3A90 Preclinical [9]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Modulator [2]

References

1 ClinicalTrials.gov (NCT04027517) A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.. U.S. National Institutes of Health.
2 DOI: 10.1038/nrneph.2015.82
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 DOI: 10.1038/nrd4422
5 Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
6 Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
7 Company report (Daiichisankyo)
8 Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
9 Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.